Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 3/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | MC4R | P32245 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | MC3R | P41968 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | P4HTM | Q9NXG6 | 3/20 | 0.42 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | NNMT | P40261 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27917292 | 0.97 | SIRT6 (0.70) | SIRT6ADORA3TSHRMC4RADRA1A | |
| SCHEMBL17712841 | 0.92 | SIRT6 (0.64) | SIRT6ADORA3TSHRMC4RADRA1A | |
| SCHEMBL2220140 | 0.87 | SIRT6 (0.59) | SIRT6ADORA3TSHRMC4RADRA1A | |
| SCHEMBL5041030 | 0.87 | SIRT6 (0.59) | SIRT6ADORA3TSHRMC4RADRA1A | |
| SCHEMBL30489429 | 0.87 | SIRT6 (0.59) | SIRT6ADORA3TSHRMC4RADRA1A | |
| SCHEMBL29757816 | 0.85 | SIRT6 (0.57) | SIRT6ADORA3TSHRMC4RADRA1A | |
| SCHEMBL147506 | 0.85 | SIRT6 (0.57) | SIRT6ADORA3TSHRMC4RADRA1A | |
| SCHEMBL2024145 | 0.85 | SIRT6 (0.57) | SIRT6ADORA3TSHRMC4RADRA1A | |
| SCHEMBL31041116 | 0.85 | SIRT6 (1.00) | SIRT6ADORA3TSHRMC4RADRA1A | |
| SCHEMBL29844782 | 0.85 | SIRT6 (0.57) | SIRT6ADORA3TSHRMC4RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4314766-A1 | METHODS OF MONITORING MUCOSAL HEALING | Medibeacon Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| US-20220326255-A1 | METHODS OF MONITORING MUCOSAL HEALING | MEDIBEACON INC. | 2022-10-13 | — | — | US | claimed |
| WO-2022212510-A1 | METHODS OF MONITORING MUCOSAL HEALING | MEDIBEACON INC. (US) | 2022-10-06 | — | — | WO | claimed |
| CN-105189506-A | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG | 2015-12-23 | — | — | CN | claimed |
| EP-3700578-B1 | SYSTEMS FOR RENAL FUNCTION DETERMINATION | MEDIBEACON INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12303570-B2 | Compositions and methods for assessing eye vasculature | MEDIBEACON INC. (US) | 2025-05-20 | — | — | US | disclosed |
| CN-114555087-B | Anodic oxidation of 5-aminouracil | 麦迪贝肯有限公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-3917378-B1 | SYSTEMS AND METHODS FOR HOME TRANSDERMAL GFR MONITORING | MEDIBEACON INC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-12102432-B2 | Uses of transdermal glomerular filtration rate measurement in continuous renal replacement therapy | MEDIBEACON, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| EP-4314766-A1 | METHODS OF MONITORING MUCOSAL HEALING | Medibeacon Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117120826-A | Method for monitoring mucosal healing | 麦迪贝肯有限公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-4243879-A1 | SUBCUTANEOUS AND INTRAMUSCULAR ADMINISTRATION OF PYRAZINE COMPOUNDS | Medibeacon Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| WO-2016183351-A1 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | MEDIBEACON INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| CN-105189506-A | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG | 2015-12-23 | — | — | CN | disclosed |
| WO-2011143540-A1 | UNIFORM, FUNCTIONALIZED, CROSS-LINKED NANOSTRUCTURES FOR MONITORING pH | MALLINCKRODT LLC (US) | 2011-11-17 | — | — | WO | disclosed |
| EP-2217281-A2 | PHOTONIC SHELL-CORE CROSS LINKED AND FUNCTIONALIZED NANOSTRUCTURES FOR BIOLOGICAL APPLICATIONS | Mallinckrodt Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-2131861-A2 | INTEGRATED PHOTOACTIVE SMALL MOLECULES AND USES THEREOF | Mallinckrodt Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009061473-A2 | PHOTONIC SHELL-CORE CROSS LINKED AND FUNCTIONALIZED NANOSTRUCTURES FOR BIOLOGICAL APPLICATIONS | MALLINCKRODT INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2008108944-A2 | INTEGRATED PHOTOACTIVE SMALL MOLECULES AND USES THEREOF | MALLINCKRODT INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-4871736-A | ANTITUMOR AGENTS | THE OHIO STATE UNIVERSITY (US) | 1989-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102432-B2 | Uses of transdermal glomerular filtration rate measurement in continuous renal replacement therapy | OGFR, PTGFR, PTAFR | SIRT6 2136/4885ADORA3 758/4885TSHR 231/4885 |
| US-20220326255-A1 | METHODS OF MONITORING MUCOSAL HEALING | FABP2, SI, SLC10A2 | SIRT6 2693/4885ADORA3 3360/4885TSHR 3954/4885 |
| US-12303570-B2 | Compositions and methods for assessing eye vasculature | LIPG, FLT4, FABP3 | SIRT6 1284/4885ADORA3 874/4885TSHR 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.